USFDA successfully concludes inspection at Syngene Bangalore facility

Published On 2022-11-16 10:00 GMT   |   Update On 2022-11-16 11:48 GMT
Advertisement

Bengaluru: Syngene International Limited has recently announced that the US Food Drug Administration (USFDA) has successfully concluded a pre-approval inspection with Zero 483 observations at the company's Biologics facility in Bangalore.

"This is to inform you that the US Food and Drug Administration (USFDA) has conducted its pre-approval inspection of the Biologics facility at Bangalore from November 07, 2022, till November 15, 2022. The inspection was completed successfully without 483 observations," the company said in a BSE filing.

The inspection was conducted from November 07, 2022, to November 15, 2022.

Read also: Syngene, Zoetis ink pact to manufacture drug substance for Librela

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. With a combination of research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News